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ABSTRACT
Immunologic mechanisms of allergen immunotherapy
are still incompletely understood. Immunotherapy of a
higher maximum tolerance dose with reduced risks of
systemic reactions, such as anaphylaxis, needs to be
developed. Seasonal allergic rhinitis (SAR) is a type I
allergic disease characterized by typical seasonal
symptoms of rhinitis and an increase in mast cells and
T helper (Th) 2-type cells, as well as tissue eosinophilia.
The present study was designed to investigate the
effect of a modified immunotherapy (IT) with an aller-
gen–pullulan conjugate (CS-560) in patients with SAR
to Japanese cedar pollen (Japanese cedar pollinosis)
using objective parameters, such as analyzing the
alteration in the proportion of effector cells like mast
cells, eosinophils and T cells, and the Th2 and Th1
cytokine profile. We also analyzed the efficacy of mod-
ified IT on the severity of symptoms, using subjective
parameters, such as the symptom–medication score.
Immunotherapy for 15 months duration with the mod-
ified drug CS-560 in patients with Japanese cedar
pollinosis induced an immune deviation from a Th2- to
a Th1-type cytokine profile and inhibited the in-season
increase in the proportion of intraepithelial mast cells
and eosinophils. These changes were associated with
a reduction in the symptom–medication score. These
data suggest that this modified IT with an allergen–
pullulan conjugate (CS-560) is an effective mode of
treatment of patients with Japanese cedar pollinosis.
Key words: eosinophil, immunotherapy, Japanese
cedar pollinossis, mast cell, seasonal allergic rhinitis,
Th1 cytokine, Th2 cytokine.
INTRODUCTION
Cross-linking of allergen-specific IgE bound to the high-
affinity IgE receptor expressed on the surface of mast cells
with multivalent antigen results in the release of inflam-
matory mediators, such as histamine, leukotrienes and
prostaglandins etc.,1–4 and in the clinical expression of
allergic disease. Seasonal allergic rhinitis (SAR) to
Japanese cedar pollen is a prototype of a type I allergic
disease that affects approximately 10–20% of the general
population in Japan. It is now evident that allergic dis-
eases are characterized by an increase in CD4+ T cells
that secrete interleukin (IL)-4, IL-5, IL-13 (T helper (Th) 
2-type cells), which not only promotes the synthesis of IgE
but also contributes to the recruitment of effector cells,
such as eosinophils and basophils, into the site of allergic
inflammation. Several studies have demonstrated the
predominance of IL-4-, IL-5- and IL-13-secreting Th2-like
activated T lymphocytes and mast cells in the nasal
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mucosa of patients with atopic rhinitis and bronchial
mucosa or bronchoalveolar lavage of patients with
atopic asthma.5–9 Upregulation of Th2-type cytokines
and a seasonal increase in intraepithelial mast cells in
patients with SAR is also well documented.10–12 Japanese
cedar pollinossis (JCP) is treated mainly with antiallergic
drugs started 1–2 weeks before the season and contin-
ued until the end of the season. Pharmacotherapy can
efficiently suppress the symptoms of pollinosis in patients
with JCP, but its effect is only symptomatic and does not
alter the course of the disease.
Ever since 1911, when Noon and Freeman attempted
to modify the symptoms of patients with allergic rhinitis
and asthma, allergen immunotherapy (IT) has been
widely used in the treatment of allergic disorders.13–18
Allergen injection IT involves the stepwise subcutaneous
injection of increasing doses of specific allergens to
which a patient is sensitive. Although the precise mecha-
nisms involved in IT are not well known, IT attempts to
alter the degree of the patient’s sensitivity to the natural
allergen (immunologic tolerance). This may result through
the induction of blocking antibodies, particularly IgG4
antibodies.15,19 Others have demonstrated that CD8+
suppressor T cells are generated during IT, which can
modulate the levels of allergen-specific IgE production.20
In addition, a reduction in intraepithelial metachromatic
cells after IT has also been reported.21 More recently, it is
believed that IT results in an alteration of cytokine profile
from a predominant Th2 response in favor of a Th1
response (interferon (IFN)-γ) resulting in a decrease in
tissue eosinophilia and specific IgE.
Despite its beneficial effects, IT has the problem of
rare but dangerous adverse systemic reactions, such 
as anaphylaxis. Novel approaches currently being
explored include the use of T cell-reactive peptides,
which may circumvent the risk of anaphylaxis, and the
use of adjuvants, such as IL-12 or mycobacterial vac-
cines, to potentiate the effects of allergen in inducing
immune deviation. Previously, we and others had
demonstrated an increase in mast cells, T cells, eosino-
phils and Th2-type cells (IL-4/IL-13) in the epithelial
compartment of the nasal mucosa of patients with SAR
(in season). In the present study, we assessed the 
efficacy of a modified IT with an allergen–pullulan con-
jugate (CS-560) in patients with JCP by analyzing the
proportion of mast cells, T cells, eosinophils and
Th2/Th1-type (IL-4/IFN-γ) cells in the epithelial com-
partment of the nasal mucosa, serum antibodies and
the clinical expression of disease.
METHODS
Allergen extract
The allergen extract (CS-560) used in the present study
was made by the conjugation of pullulan (a-1,4′-a-1,
6′-glucan), a neutral polysaccharide, with Cry j 1 and 2
(purified allergenic substances from Japanese cedar
pollen), by the collaboration of Hayashibara Biochemical
Institute (Tokyo, Japan) and Sankyo Pharmaceutical Co.
(Tokyo, Japan) and is characterized by weak allergenicity,
but strong antigenicity, having an immunologic profile of
allergen and stable antigen titre. This extract is supplied
as a solution of 200 ng CS-560 (Cry j1 : Cry j2 = 4.1)
and 0.3 mg human serum albumin/mL solution.
Subjects
Ten patients with JCP (four males and six females; all
Japanese) ranging in age from 19 to 45 years were
selected after careful screening and definite diagnosis of
SAR to Japanese cedar pollen. All patients were selected
on the basis of a well-documented history of seasonal
attacks of sneezing, rhinorrhea and nasal obstruction in
the season of JCP (from the first week of February to the
end of April), no history of asthma, clinical examination
by anterior rhinoscopy and allergy tests, including in vitro
tests for specific IgE (capsulated hydrophobic carrier
polymer–radioallergosorbent (CAP-RAST) test), skin-prick
tests and nasal provocation test. Any associated nasal
diseases, such as sinusitis, were excluded by clinical and
X-ray examination. These 10 patients were given IT with
an allergen–pullulan conjugate after their informed con-
sent had been obtained. No concomittant treatment with
pharmacotherapeutic agents was allowed in patients in
the IT group except in-season when the symptoms were
intolerable, in which case these patients were given
oral antihistamines (clemastine fumarate; Sandoz, Basel,
Switzerland) as rescue medication. In order to exclude
the influence of this rescue medication on the results of IT,
we included a pharmacotherapy group comprising 10
patients with JCP (five males and five females; all Japanese)
ranging in age from 19 to 41 years and selected by the
same criteria as for the IT group. Patients in the control
(pharmacotherapy) group were prescribed only oral anti-
histamines (clemastine fumarate or pemirolast; Tokyo
Tanabe, Tokyo, Japan). None of the patients in the
control (pharmacotherapy) group had previously been
treated with IT or was receiving steroids. All patients with
JCP were symptomatic in-season and had a CAP-RAST
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score greater than grade 3. Two of 10 patients with JCP
in the IT group and one of the patients in the control
(pharmacotherapy) group had associated nasal allergy to
house dust mite (HDM).
Study design
Immunotherapy was commenced in January 1996 for a
period of 2 years. The period of this study was from
December 1995 to June 1997 (until 18 months post-IT),
covering two  seasons of JCP (1996 and 1997).
Specimens of the nasal epithelial layer (nasal scrapings)
were collected by gently scraping the anterior surface of
the inferior turbinates (bilaterally) with a small surgical
curette (cup size 2 x 3 mm). Nasal scrapings were col-
lected over two seasons, twice off-season (before starting
IT and 13 months after starting IT) and in-season (3 and
15 months after starting IT) and finally off-season at 18
months after IT. Nasal scrapings were also collected from
the control group at the same time points. Analysis of the
proportion of mast cells, lymphocytes, eosinophils and 
IL-4- (Th2-type cytokine) and IFN-γ-expressing (Th1-type
cytokine) cells in nasal scrapings (epithelial compartment)
was performed by immunohistochemistry. Specimens were
coded and blinded. Venous blood was collected twice
from each patient, before and during the season, for 
the analysis of serum-specific IgE and IgG4. The clini-
cal expression of disease was analyzed using subjec-
tive parameters, such as the symptom score and the
symptom–medication score, as described later, and ana-
lyzed from the patient’s record of an allergy diary. In the
present study, we included a pharmacotherapy group as
a control, because we had no placebo controls due to
difficulty in getting informed consent.
Mode of IT
Patients were given subcutaneous injections of CS-560
with prior informed consent. Taking into consideration the
end-point concentration determined by the intracutaneous
titration technique using a series of 10-fold dilutions of
CS-560 at concentrations of 0.002–200 ng/mL, the
individual initial dose was determined. Doses were
increased weekly from 0.1, 0.3 and 0.5 mL at the thresh-
old concentration to the highest tolerated concentration
(usually 0.5 mL of 200 ng/mL). The maximum tolerated
dose was attained in approximately 3 months with the
once a week program. Weekly injection of this dose was
continued for the first few months after attainment of the
maintenance dose. Patients then received injections of
this dose on a bi-weekly basis for the next 4 months and
then monthly injections. After each injection, the patient
was kept under supervision for a minimum of 30 min.
Monoclonal antibodies
The anti-IL-4 monoclonal antibody (mAb; DNAX, Palo
Alto, CA, USA), antitryptase (Chemicon, Temecula, CA,
USA), anti-CD3/anti-CD4 (Dako Patts, Palo Alto, CA,
USA); anti-IFN-γ (Genzyme, Cambridge, MA, USA) and
anti-EG2 (Pharmacia, Uppsala, Sweden), and mouse
IgG1/rat IgG1 negative controls (Dako Patts) were
obtained commercially.
Estimation of the levels of serum-specific IgE
and IgG4 antibodies
The levels of serum IgE (CAP-RAST; Pharmacia) and IgG4
antibodies were estimated by sandwich ELISA.
Collection of specimens and experimental
schedule
Specimens were collected from the IT group as shown in
Fig. 1, off-season before starting IT in December 1995,
at the peak of the JCP season 3 months after starting IT
(first week of March 1996), off-season at 13 months after
starting IT (January 1997) and at the peak of the second
JCP season 15 months after IT (first week of March
1997), and then off-season 18 months after starting IT.
Specimens were also collected from the control group
off-season and in-season in 1996 and 1997. Nasal
scrapings were obtained by gently scraping the anterior
surface of the nasal inferior turbinates (bilaterally) using a
small surgical curette (cup size 2 × 3 mm). The scrapings
were fixed in periodate polylysine paraformaldehyde
(PLP) for 15 min, washed in phosphate-buffered saline
(PBS; pH 7.4) with 15% sucrose, cytospinned onto silane-
coated slides and stored air-tight at –80°C until further
use.
Immunohistochemistry for the analysis of
mast cells, T cells and eosinophils
Analysis of the proportion of mast cells (tryptase-positive
cells), T lymphocytes (CD3+ cells) and eosinophils (EG2-
positive cells) was performed by staining with the relevant
mAbs using the alkaline phosphatase antialkaline phos-
phatase (APAAP) method (Dako APAAP kit). Briefly, for the
staining of mast cells, eosinophils and T lymphocytes,
specimens were air-dried, rehydrated in Tris-buffered
saline (TBS; pH 7.6), pretreated with 10% normal rabbit
serum for 15 min and then incubated in saturating 
concentrations of the relevant primary mAbs for 1 h.
Subsequently, specimens were incubated in rabbit anti-
mouse IgG for 30 min and then with the APAAP reagent
for 30 min. Between each incubation, the specimens
were rinsed in TBS. The reaction was developed by incu-
bating specimens in the substrate Naphthol AS-MX
Fast-Red TR (Dako Patts, Palo Alto, CA, USA). Finally,
specimens were rinsed in distilled water, counterstained
with Mayer’s hematoxylin and mounted in Dako gel.
Negative controls were obtained by substituting the
primary mAb with an isotype-matched unrelated mAb
(Mouse myeloma IgG1; Dako).
Immunohistochemistry for the analysis of 
IL-4- and IFN-γ-positive cells
Analysis for the proportion of IL-4+ and CD4+ cells was
performed by double staining with the relevant mAbs using
the avidin–biotin and indirect immunofluorescence method.
Briefly, specimens were air-dried, permeabilized by incuba-
tion in PBS supplemented with 25 mm HEPES (hemisodium
salt) and 0.1% saponin (PBS–saponin), pretreated with
10% normal rabbit serum serum for 15 min and then incu-
bated overnight at 4°C with the relevant primary mAbs
(anti-IL-4/IFN-γ mAb), stained by the biotin–streptavidin
horseradish peroxidase method (ABC kit; Vector Labor-
atories, Palo Alto, CA, USA) as described previously.22,23
Specimens were then treated with 10% normal goat serum,
the anti-CD4 mAb and fluorescence isothiocyanate
(FITC)-conjugated antimouse IgG. Between each incuba-
tion, specimens were rinsed twice in PBS–saponin.
Finally, specimens were rinsed in distilled water (DW) and
mounted in Dako gel. Negative controls were obtained
using isotype-matched unrelated mAbs. Results were exam-
ined with a Nikon fluorescent microscope (Tokyo, Japan).
Cell counting
The proportion of mast cells, T cells and eosinophils in
nasal scrapings was assessed by counting the numbers of
tryptase-positive, CD3+ and EG2-positive cells and total
infiltrating cells in an area of 0.202 mm2 (× 200 h.p.f.)
using an objective micrometer and then calculating the
percentage of each cell type per hundred infiltrating cells.
To determine the proportion of CD4+ IL-4-positive and
CD4+ IFN-γ-positive cells, we counted the number of
double-positive cells and CD4+ cells in an area of
0.202 mm2 (× 200 h.p.f.) using an objective micrometer
and calculated the percentage of CD4+ IL-4-positive or
CD4+ IFN-γ-positive cells per hundred CD4+ cells. An
average of six fields per specimen was taken as the final
value.
Assessment of clinical expression of disease
Nasal symptoms were scored on the basis of the number
of sneezes, the number of nose blowings and the degree
of nasal obstruction, as described previously.24,25 Briefly,
patients were asked to maintain an allergy diary to note
their daily symptoms and the grading of severity was
assessed on a scale from 1 to 4 as described previously:24
1+, mild; 2+, moderate; 3+, severe; and 4+, very
severe. The medication score was calculated on the basis
of the kinds and combination of drugs the patient was
taking (score 1, second generation antihistamines or
anticholinergics/vasodilators; score 2, topical steroids;
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Fig. 1 Experimental schedule for the collection of specimens. Specimens of nasal scrapings were collected at the indicated time
points, off-season before starting immunotherapy (IT), at the peak of the Japanese cedar pollinossis (JCP) season 3 months after
starting IT, off-season at 13 months after staring IT, at the peak of the JCP season 15 months after IT and, finally, off-season 18
months after IT.
and score 4, oral steroids), as described previously.26
Finally, the symptom–medication score was calculated
from the symptom and medication score as shown in
Table 1 and as described previously.26
Statistical analysis
Results are expressed either as the mean ± SD or as the
median and interquartile range. For intergroup compari-
son, the Mann–Whitney U-test (STAT View, Berkeley, CA,
USA) was used. For comparison of values within a group,
Wilcoxon’s signed-rank test (STAT View) was used. The
correlation coefficient was estimated by Spearman’s rank
correlation analysis. Statistically significant differences
were accepted when P < 0.05.
RESULTS
Background of the subjects
There were no significant differences in sex or age
between the 10 patients in the IT group and the 10
patients in the control group (Table 2). Neither was there
any statistically significant difference in the levels of
serum-specific IgE or skin tests between the two groups.
Total pollen counts in 1996 and 1997
The total pollen count in-season in the Tokyo area from
where the patients came was 943 cm2 for 1996 and
2768/cm2 for 1997 (Fig. 2).
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Table 1 Background of the subjects
Group Sex Age (years) sIgE (IU/mL) Skin test
No. No. JCP HD
males females
IT (n = 10) 4 6 28.6±9.8 (19–45) 30.1±16.2 1.9±0.7 (1–3) 1
Controls (n = 10) 5 5 30.6±8.6 (19–41) 33.3±12.8 2.1±0.7 (1–3) 1
Where appropriate, data are the mean±SD with the range given in parentheses.
IT, immunotherapy; sIgE, soluble IgE; JCP, Japanese cedar pollinossis; HD, house dust.
Table 2 Classification of the symptom–medication score
Type of medication Nasal symptoms
1 No medication 0 1 2 3 4
2 Oral antihistamines/mast cell stabilizers 1 2 3 4 5
3 Topical steroids 2 3 4 5 6
4 Oral antihistamines/mast cell stabilizers + topical steroids 3 4 5 6 7
5 4 + others (oral steroids) 4 5 6 7 8
Fig. 2 Pollen counts for the
Japanese cedar pollinossis
(JCP) season in 1996 () and
1997 (). Total pollen counts
in-season, in the Tokyo area
from where the patients came
was 943 cm2 for 1996 and
2768 cm2 for 1997.
Comparison of IL-4-positive CD4+ cells (Th2),
IFN-γ-positive CD4+ cells (Th1), mast cells,
eosinophils and T lymphocytes in nasal
epithelial compartment of IT and control
groups in 1996 (off-season vs in-season)
The proportion of IL-4-positive CD4+ and tryptase-
positive cells in nasal scrapings (nasal epithelial compart-
ment) were modestly but not significantly increased
in-season (3 months after starting IT) compared with levels
observed during the off-season (before starting IT; 
Fig. 3a,c). In contrast, the proportion of IFN-γ-positive
CD4+ and CD3+ cells was not increased in-season
compared with the off-season (Fig. 3b,e). The pro-
portion of EG2-positive cells (eosinophils) in the 
nasal epithelial compartment was increased in-season 
(3 months after starting IT) compared with off-season
(Fig. 3d).
In the control group, the proportion of IL-4-positive
CD4+ cells, tryptase-positive cells (mast cells) and EG2-
positive cells (eosinophils) was increased in-season
compared with the off-season (Fig. 3). No significant 
differences were observed in the percentage of IFN-γ-
positive CD4+ cells or CD3+ cells (T cells).
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Fig. 3 The proportion of (a) interleukin (IL)-4-positive CD4+
cells, (b) interferon (IFN)-γ-positive CD4+ cells, (c) mast cells, 
(d) eosinophils and (e) T cells in the nasal epithelial compart-
ment of the immunotherapy (IT) and control groups for 
off- versus in-season in 1996, as analyzed by immuno-
histochemistry and counted as described in the text. **P < 0.01
compared with in-season.
Comparison of IL-4-positive CD4+ cells (Th2),
IFN-γ-positive CD4+ cells (Th1), mast cells,
eosinophils and T lymphocytes in the nasal
scrapings of the IT and control groups in
1997 (off-season vs in-season)
In-season in 1997 (15 months after starting IT), the 
proportion of IL-4-positive CD4+, tryptase-positive, EG2-
positive and CD3+ cells was not increased in-season
compared with the off-season (Fig. 4a,c,d). In contrast,
the proportion of IFN-γ-positive CD4+ cells was increased
in-season (15 months after starting IT) compared with the
off-season.
In the control group, the percentage of IL-4-positive
CD4+, tryptase-positive and EG2-positive cells increased
significantly in-season compared with the off-season
(Fig. 4). No significant changes were observed in the 
proportion of IFN-γ-positive CD4+ cells or CD3+ cells 
in-season compared with the off-season.
Although no significant differences were detected in
the proportion of IL-4-positive CD4+, tryptase-positive
and EG2-positive cells between the IT and control
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Fig. 4 The proportion of (a) interleukin (IL)-4-positive CD4+
cells, (b) interferon (IFN)-γ-positive CD4+ cells, (c) mast cells, 
(d) eosinophils and (e) T cells in the nasal epithelial compart-
ment of the immunotherapy (IT) and control groups for 
off- versus in-season in 1997, as analyzed by immunohisto-
chemistry and counted as described in the text. **P < 0.01
compared with in-season.
groups at baseline, the selective increase of these 
cell types in the control group suggests that IT inhibited
the seasonal increase in these cell types in the IT 
group.
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Fig. 5 Comparison of the proportion of (a) interleukin (IL)-4-
positive CD4+ cells, (b) interferon (IFN)-γ-positive CD4+ cells, 
(c) mast cells, (d) eosinophils and (e) T cells in the nasal epithe-
lial compartment of the immunotherapy (IT) group 18 months
after starting IT () compared with pre-IT ( ), as analyzed by
immunohistochemistry and counted as described in the text.
**P < 0.01 compared with pre-IT.
Comparison of the proportion of IL-4-positive
CD4+ cells (Th2), IFN-γ-positive CD4+ cells
(Th1), mast cells, eosinophils and T cells in
the nasal scrapings of the IT group 
18 months after IT (off-season) compared
with pre-IT
The percentage of IL-4-positive CD4+, tryptase-positive
and EG2-positive cells was significantly less in the IT
group 18 months after IT compared with that before 
starting IT (pre-IT; P < 0.01; Fig. 5). In contrast, the pro-
portion of IFN-γ-positive CD4+ cells in the IT group
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Fig. 6 Symptom–medication (S-M) score in the immunotherapy
(IT; ) and control () groups. The S-M score was calculated as
described previously.23 (a) The S-M score in the IT group at the first
season in 1996 (3 months after starting IT) was not statistically 
different from that of controls. (b) However, the S-M score in the 
IT group in the second season, in 1997 (15 months after starting
IT), was significantly lower compared with that of the control
group. **P < 0.01 compared with the control group.
Fig. 7 Levels of serum (a) IgE and (b) IgG4 antibodies in the
immunotherapy (IT) group at 18 months after IT () compared
with pre-IT (). The levels of serum IgE and IgG4 were 
analyzed by ELISA as described in the text. (a) Levels of serum
IgE were not altered in the IT group 18 months after treatment 
compared with levels pre-IT. (b) In contrast, levels of serum
IgG4 antibodies in the IT group were significantly increased 
18 months after treatment compared with pre-IT. **P < 0.01
compared with pre-IT.
increased significantly compared with pre-IT (P < 0.01).
No significant difference was detected in the proportion
of CD3+ cells 18 months after IT compared with pre-IT.
Clinical expression of disease in the IT and
control groups
The symptom–mediation score (S-M score) in the IT
group in-season in 1996, 3 months after starting IT, was
not significantly different compared with that of the
control group (Fig. 6a). However, the S-M score in the 
IT group in-season in 1997, 15 months after starting IT,
was significantly lower compared with that of the control
group (Fig. 6b).
Levels of serum IgE and IgG4 antibodies
The levels of serum-specific IgE in the IT and control
groups were not different at baseline (Table 1). Even at
18 months after IT, no statistically significant difference
was noted in the levels of serum-specific IgE compared
with pre-IT (Fig. 7a). In contrast, the levels of IgG4 anti-
bodies were significantly increased in the IT group at
18 months after starting treatment compared with levels
pre-IT (Fig. 7b).
Correlation between the S-M score and
immunologic parameters in the IT group
In order to assess any probable parameters that could
reflect the clinical efficacy of IT, we examined the correla-
tion between the S-M score and various immunologic
parameters, such as the proportion of mast cells,
eosinophils, T cells, IL-4- or IFN-γ-positive cells, serum
IgE and IgG4. We only found a good correlation
between the proportion of IL-4-positive CD4+ cells and
the S-M score (r = 0.76, P < 0.007 in-season in 1996;
r = 0.6, P < 0.04 in-season in 1997).
DISCUSSION
Specific allergen injection IT is highly effective in selected
patients with IgE-mediated disease, including respiratory
allergy and venom anaphylaxis.15 Research in this area
provides insight into the immunologic basis of allergic
disease. The present study was designed to evaluate
whether modified IT with an allergen–pullulan conjugate
(CS-560) could alter the local mucosal cytokine profile
and cellular population and whether those changes
could reflect the clinical efficacy of treatment. Although in
the present study we had no placebo controls due to diffi-
culty in obtaining informed consent, we have included a
pharmacotherapy group as the control group.
One way in which IT may act is by modifying the T lym-
phocyte response to subsequent natural allergen exposure.
Studies in peripheral blood and within the target organ
have demonstrated a shift in the balance of T cell subsets
away from the Th2-type (producing, particularly, IL-4 and
IL-5) in favor of a Th1-type T lymphocyte response (with
the preferential production of IFN-γ).27–29 Interleukin-4
is a key cytokine that is known to play a crucial role in 
the development and perpetuation of the allergic reac-
tion through the synthesis of IgE, development of
Th2-type cells, upregulation of adhesion molecules, such
as vascular cell adhesion molecule-1 and upregulation
of FcεRI expression in mast cells.22 Our results exhibited
an inhibition of the seasonal increase in the proportion of
IL-4-positive cells. In contrast, IT induced an increase 
in IFN-γ-positive cells. Yet, no difference was observed 
in the proportion of lymphocytes before and after treat-
ment. Using sugi basic protein (SBP)-specific T cell lines
and clones from BALBc mice, it was recently shown that
repeated cycles of stimulation of the cell lines with the
SBP–pullulan conjugate resulted in a polarization of the 
T cell response towards a Th1-like pattern of cytokine
production, essentially augmentation of IFN-γ production
and inhibition of IL-4, IL-5 and IL-10 production.24
Furthermore, IL-4 production by the Th2 clones was
almost completely abrogated in response to SBP–
pullulan. This was not due to anergy of these cells
because significant proliferation was observed in these 
T cell lines in response to SBP.27 Thus, the allergen–pullulan
conjugate can downregulate IL-4 expression (Th2-type
cells) and upregulate the IFN-γ (Th1) cells. These obser-
vations can be compared with our present data that IT
with the allergen-pullulan conjugate did not affect the
proportion of lymphocytes, but only inhibited the sea-
sonal increase in IL-4-positive CD4+ cells (Th2-type
cells), thereby inducing an immune deviation from a Th2
to a Th1 profile.
It has been shown that modification in the T cell recep-
tor (TCR) contact residue of an antigen can cause
qualitative differences in the effector phase of the
immune response.28 In view of this, one may speculate
that when pullulan binds to an amino acid residue of SBP
within or near the TCR contact region, the conjugate may
transmit qualitatively different signals leading to quantita-
tive and qualitative variations in cytokine production.
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It is said that IT reduces allergen-induced immediate-
phase symptoms and concentrations of inflammatory
mediators, including histamine and prostaglandin D2, in
the nasal fluid of ragweed-sensitive patients.21 Similarly,
nasal epithelial mast cell numbers have been reported to
be decreased after IT.29 A characteristic feature of IT is 
its ability to inhibit late-phase responses.30,31 In the nose,
IT is accompanied by a decrease in eosinophil numbers
in lavage during late responses.32 In the present study, we
found that this modified IT inhibited the seasonal increase
in mast cells and eosinophils, 15 months after staring IT
(compared with controls). Because the mast cell is the
central cell in the immediate-phase allergic reaction and
the eosinophil is a key cell in the late-phase allergic 
reaction, these results suggest that IT with CS-560 
can probably suppress the early as well as late-phase
responses. Moreover, because mast cells are an impor-
tant source of Th2-type cytokines (IL-4, IL-5, IL-6, IL-13),
the reduction in mast cell numbers may contribute to
reduced IL-5 production and, thereby, a reduction in
tissue eosinophilia. Still further, the IT-induced inhibition
in the seasonal increase of IL-4-positive cells and the 
IT-induced upregulation of IFN-γ-positive cells can also
contribute to downregulating mast cell mediator release,
because IL-4 upregulates FcεRI expression and mediator
release from mast cells/basophils,22,33 whereas IFN-γ
reciprocally downregulates it.34 Most importantly, the
alteration in immunologic parameters was associated
with a reduction in the symptoms of the patients.
At baseline, in both the control and IT groups, IL-4-
positive cells, eosinophils and mast cells were detectable
in the nasal epithelial compartment. This could be
explained by the more recent understanding of the
concept of minimal persistant inflammation (MPI),35
which is the existence of minimal levels of inflammation
even in the absence of symptoms. Although some of the
patients had associated nasal allergy to HDM, there was
no major difference between those who had associated
nasal allergy to HDM and those who did not. The present
data, demonstrating a significant decrease in the propor-
tion of IL-4-positive cells, eosinophils and mast cells in
the nasal epithelial compartment at 18 months after IT
compared with baseline values pre-IT, suggest that IT
may also be effective in downregulating MPI.
It was previously postulated that IT could decrease the
levels of IgE, but this reduction may require several years.
Characteristic changes in serum immunoglobulins have
been reported, with an initial increase in IgE followed by
a blunting of seasonal increases in IgE in pollen-sensitive
patients and a gradual decline in allergen-specific IgE
levels over several years.36 This is accompanied by an
increase in allergen-specific IgG (blocking antibodies),
although neither appear to correlate closely with the 
clinical response to IT.36 In the present study, we found
no marked reduction in the level of serum-specific IgE,
even at 18 months after starting treatment. However, the
levels of IgG4-blocking antibodies was significantly
increased from 15 to 18 months after starting IT. Yet,
serial monitoring of the levels of IgE and IgG4 for
several years is essential to precisely evaluate their clini-
cal significance.
Although in the present study the total number of
patients was too few to comment on the safety of IT, in a
separate larger clinical trial using this modified IT it was
found that the incidence of anaphylaxis with CS-560
was less than 0.3% (unpubl. data). This may because
the pullulan of the allergen–pullulan conjugate binds to
one of the IgE molecules, thus preventing the cross-
linking of two adjacent IgE molecules by the allergen.
Thus, this modified IT can induce immunologic toler-
ance to the natural allergen, without the risk of causing
systemic reaction. Moreover, in addition to the safety
and efficacy of this modified IT on various immunologic
parameters, in separate studies it has also been ob-
served that this modified IT improves the quality of life of
patients (unpubl. data).
Thus, taken together, these results suggest that this
modified IT with the allergen–pullulan conjugate CS-560
is effective, as assessed by both objective and subjective
parameters. Moreover, the clinical benefit of this IT can
be attributed to an inhibition of the seasonal increase in
the proportion of effector cells, such as mast cells and
eosinophils, and an immune deviation from a Th2 to a
Th1 cytokine profile and perhaps also a rise in blocking
antibodies.
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